Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir

Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced... Downloaded from http://journals.lww.com/jaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/12/2020 BRIEF REPORT:CLINICAL SCIENCE Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir Sandra M. J. De Meyer, PhD, Sabrina Spinosa-Guzman, MD, Tony J. Vangeneugden, PhD, Marie-Pierre de Be ´thune, PhD, and G. Diego Miralles, MD INTRODUCTION Objective: The objective of this study was to examine the potential Once-daily protease inhibitor (PI)–based highly active of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV- antiretroviral therapy would be more convenient in an era infected, treatment-experienced patient population with no baseline where there are new, increasingly potent, once-daily antire- darunavir resistance–associated mutations (RAMs). troviral agents with improved tolerability. The efficacy and tolerability of the HIV-1 PI darunavir (TMC114) coadminis- Methods: Patients in the randomized controlled POWER 1 and tered with low-dose ritonavir (darunavir/r) at a dose of 800/100 2 trials were treatment experienced, with $1 International AIDS mg once daily are being compared with lopinavir/r 800/200 Society-USA primary protease inhibitor (PI) mutation. The virological mg total daily dose in an antiretroviral-naive HIV-1–infected and immunological responses in patients with no baseline darunavir population in the ongoing Phase III ARTEMIS trial. At 48 RAMs receiving darunavir/r 800/100 mg http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAIDS Journal of Acquired Immune Deficiency Syndromes Wolters Kluwer Health

Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir

Loading next page...
 
/lp/wolters-kluwer-health/efficacy-of-once-daily-darunavir-ritonavir-800-100-mg-in-hiv-infected-0gwz5M5JF5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1525-4135
eISSN
1077-9450
DOI
10.1097/QAI.0b013e318183a959
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/jaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/12/2020 BRIEF REPORT:CLINICAL SCIENCE Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir Sandra M. J. De Meyer, PhD, Sabrina Spinosa-Guzman, MD, Tony J. Vangeneugden, PhD, Marie-Pierre de Be ´thune, PhD, and G. Diego Miralles, MD INTRODUCTION Objective: The objective of this study was to examine the potential Once-daily protease inhibitor (PI)–based highly active of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV- antiretroviral therapy would be more convenient in an era infected, treatment-experienced patient population with no baseline where there are new, increasingly potent, once-daily antire- darunavir resistance–associated mutations (RAMs). troviral agents with improved tolerability. The efficacy and tolerability of the HIV-1 PI darunavir (TMC114) coadminis- Methods: Patients in the randomized controlled POWER 1 and tered with low-dose ritonavir (darunavir/r) at a dose of 800/100 2 trials were treatment experienced, with $1 International AIDS mg once daily are being compared with lopinavir/r 800/200 Society-USA primary protease inhibitor (PI) mutation. The virological mg total daily dose in an antiretroviral-naive HIV-1–infected and immunological responses in patients with no baseline darunavir population in the ongoing Phase III ARTEMIS trial. At 48 RAMs receiving darunavir/r 800/100 mg

Journal

JAIDS Journal of Acquired Immune Deficiency SyndromesWolters Kluwer Health

Published: Oct 1, 2008

There are no references for this article.